Who asks about CJC-1295 and what they want to know
CJC-1295 draws questions from two overlapping groups: people who have already researched growth hormone secretagogues and want to understand how CJC-1295 differs from sermorelin, and people who have seen CJC-1295 discussed alongside ipamorelin and want to understand the rationale.
Who asks about CJC-1295
The people who ask are often similar to those who ask about sermorelin: adults — typically men in their 40s and 50s — noticing gradual loss of lean mass despite consistent exercise, worsening sleep quality, slower recovery, or the particular kind of fatigue that full nights of sleep do not resolve.
These symptoms have many causes and do not automatically mean GH deficiency. A physician evaluation — which includes IGF-1 levels from a comprehensive midlife panel — establishes whether declining GH output is a meaningful contributor. IGF-1 (insulin-like growth factor 1 — in plain English: the downstream marker the liver produces in response to GH) is the most practical lab proxy for GH status without complex stimulation tests.
What does CJC-1295 do
CJC-1295 is a synthetic GHRH analog — like sermorelin, it is designed to stimulate the pituitary gland to release growth hormone through the body's own pathway rather than introducing exogenous GH directly. The key pharmacological difference is half-life.
Sermorelin clears the body within minutes of injection. Natural GHRH works similarly — brief pulses that prompt pituitary response. CJC-1295 was engineered for extended duration. The version with DAC (Drug Affinity Complex — in plain English: a chemical modification that binds to albumin in the blood and extends the molecule's lifespan) remains active for days rather than minutes. A 2006 study in Journal of Clinical Endocrinology & Metabolism found that, in healthy adults, a single CJC-1295 injection raised GH levels for 6 days or more and IGF-1 levels for 9 to 11 days.
What is the difference between CJC-1295 and sermorelin
Both work on the same GHRH receptor. Duration is the main pharmacological difference. Sermorelin mimics the natural episodic GH pulse. CJC-1295 (with DAC) produces more sustained elevation. Without DAC, CJC-1295 has an intermediate half-life closer to natural GHRH.
CJC-1295 without DAC is often discussed alongside ipamorelin (a ghrelin mimetic that acts on a separate GH-stimulating pathway). That pairing is a mechanistic idea, not an established treatment. The 2006 study above measured hormone levels, not health outcomes, and effects on health outcomes have not been shown in people.
Where CJC-1295 stands with FDA
FDA has not approved CJC-1295. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Frequently asked questions
Who asks about CJC-1295?
Mostly adults in midlife who have read about growth hormone secretagogues and want to know how CJC-1295 differs from sermorelin, or who have seen it discussed alongside ipamorelin. Symptoms such as reduced lean mass, poor sleep or slow recovery have many causes and do not by themselves mean low growth hormone.
What does CJC-1295 do?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate the pituitary gland to secrete growth hormone. In a 2006 study in healthy adults, a single injection raised growth hormone levels for 6 days or more and IGF-1 levels for 9 to 11 days. Effects on health outcomes have not been shown in people.
What is the difference between CJC-1295 and sermorelin?
Both are GHRH analogs that stimulate pituitary GH release. The key difference is half-life: sermorelin clears the body in minutes; CJC-1295 (with DAC) remains active for days. CJC-1295 without DAC has an intermediate duration.
Why is CJC-1295 often discussed with ipamorelin?
Ipamorelin is a ghrelin mimetic that acts on a different receptor pathway than GHRH. The idea behind discussing them together is that they act on two separate growth hormone pathways. That is a mechanistic idea, not an established treatment, and this page does not recommend using them together.
What is CJC-1295's FDA status?
Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
